Jennifer C. Cather, MD, FAAD

Modern Research Associates

9101 North Central Expressway, Suite 170
Dallas, Texas, United States
75231
214-361-2008

 

Specialty: Dermatology

Research Interests: Acne, Aesthetics, Atopic Dermatitis (Eczema), Cutaneous Lymphoma, Graft vs. Host disease, Psoriasis, Psoriatic Arthritis

Dr. Jennifer Cather has been practicing dermatology since 1999. Dr. Cather is actively involved in clinical research, and has been working on clinical trials since 1995. Dr. Cather has been involved with over 134 clinical trials since 1999. In 2008, Dr. Cather opened Modern Research Associates to focus on clinical trials in dermatology for conditions including psoriasis, eczema and psoriatic arthritis. 

Dr. Cather is presently the Medical Director for both Modern Research Associates and Modern Dermatology in Dallas. She is also the Co-Director of the Graft vs. Host Clinic and the Cutaneous Lymphoma Clinic, at Baylor University Medical Center.

Dr. Cather is certified by both the Medical Board of California and the Texas Medical Board. 

 

Click to View Dr. Jennifer Cather's Publications

Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, Day RM, Chen R, Shah K, Ferrándiz C, Cather JC. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017 Aug; 77(2): 310-7. Epub 2017 Apr 14. PMID: 28416342 / doi: 10.1016/j.jaad.2017.01.052

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017 Jun 10; 389(10086): 2287-303. Epub 2017 May 4. PMID: 28478972 / doi: 10.1016/S0140-6736(17)31191-1

Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12 week results from two phase 3 trials. J Eur Acad Dermatol Venereol 2017 Jun 2 [Epub ahead of print]. PMID: 28573743 / doi: 10.1111/jdv.14377

Cather JC, Young M, Bergman MJ. Psoriasis and psoriatic arthritis. J Clin Aesthet Dermatol 2017 Mar; 10(3): S16-S25. Epub 2017 Mar 1. PMID: 28360971

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb) 2016 Dec; 6(4): 639-47. Epub 2016 Aug 30. PMID: 27576559

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016 Aug; 175(2): 273-86. Epub 2016 Jun 23.  PMID: 26914406 / doi: 10.1111/bjd.14493

Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S. Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials. J Drugs Dermatol 2016 May 1; 15(5): 568-580. PMID: 27168266

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015 Dec; 173(6): 1387-99. Epub 2015 Nov 7. PMID: 26357944 / doi: 10.1111/bjd.14164

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4): 949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Cather JC, Horn EJ. Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. Clin Investig 2015; 5(9): 777-91. [Epub ahead of print]. doi: 10.4155/cli.15.50

Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol 2014 Dec; 15(6): 467-78. PMID: 25373522 / doi: 10.1007/s40257-014-0097-1

Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014 Nov; 13(11): 1380-6. PMID: 25607706

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014 Jul 24; 371(4): 326-38. Epub 2014 Jul 9. PMID: 25007392 / doi: 10.1056/NEJMoa1314258

Cather JC. Psoriasis in children and women: addressing some special needs. Semin Cutan Med Surg 2014 Mar; 33(2 Suppl 2): S42-4. PMID: 24979545 / doi: 10.12788/j.sder.0066

Furst DE, Mandell B, Calabrese LH, Cather JC, Clauw DJ, Deodhar A, Kremer JM, Lewiecki EM, McMahon M, T Ritchlin C. Proceedings of the 5th annual perspectives in rheumatic diseases. Semin Arthritis Rheum 2013 Dec; 43(3): 416-9. PMID: 24326035 / doi: 10.1016/j.semarthrit.2013.06.002

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 2. Dermatol Ther (Heidelb) 2012 Dec; 2(1): 2. Epub 2012 Mar 30. PMID: 23205325 / doi: 10.1007/s13555-012-0002-x

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 1. Dermatol Ther (Heidelb) 2012 Dec; 2(1): 1. Epub 2012 Mar 17. PMID: 23205324 / doi: 10.1007/s13555-012-0001-y

Abramovits W, Oquendo M, Granowski P, Gupta A, Cather J. Pralatrexate (Folotyn). Skinmed 2012 Jul-Aug; 10(4): 244-6. PMID: 23008944

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012 Aug 25; 380(9843): 738-46. Epub 2012 Jun 29. PMID: 22748702 / doi: 10.1016/S0140-6736(12)60642-4

Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol 2011 Jan; 7(1): 9-13. PMID: 21162644 / doi: 10.1586/eci.10.92

Meier AP, Cather JC. Blanched fingers. Proc (Bayl Univ Med Cent) 2010 Jan; 23(1): 73-5. PMID: 21240308

Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol 2009 Jul; 61(1 Suppl 1): S1-S46. PMID: 19527820 / doi: 10.1016/j.jaad.2009.03.017

Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC.  AJC editor's consensus: psoriasis and coronary artery disease.  Am J Cardiol 2008; 102(12):1631-43. 

Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC.  The Editor's Roundtable: Psoriasis, Inflammation, and Coronary Artery Disease.  Am J Cardiol.  2008; 101(8):1119-1126. 

Cather JC.  Asymptomatic translucent dome-shaped cystic nodule on the finger.  Proc (Bayl Univ Med Cent) 2008; 21(2):183. 

Cather JC.  Asymptomatic golden macule on the ankle.  Proc (Bayl Univ Med Cent) 2008; 21(1):73-74. 

Perlmutter A, Cather J, Franks B, Jaracz E, Menter A. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008 Jan; 58(1): 116-24. PMID: 17997502

Cather JC, Hoffman L. Weepy pruritic rash in the groin.  Proc (Bayl Univ Med Cent) 2007; 20(4):402-403. 

Cather JC.  Perirectal pruritus.  Proc (Bayl Univ Med Cent) 2007; 20(3):303-304. 

Cather JC, Cather JC.  Hypertrophic and atrophic scars.  Proc (Bayl Univ Med Cent) 2007; 20(2): 184-186. 

Cather JC.  Bumps on the hand.  Proc (Bayl Univ Med Cent) 2006; 19(3):277-278. 

Cather JC.  Pruritic eruption on the anterior shins.  Proc (Bayl Univ Med Cent) 2006; 19(4):409-410. 

Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A.  A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.  Dermatology 2006; 213(3):204-214. 

Cather JC.  Papule on the dorsal foot.  Proc (Bayl Univ Med Cent) 2006; 19(2):151-152. 

McQuade J, Cather JC.  Fever and malaise associated with a painful papule on the ankle.  Proc (Bayl Univ Med Cent) 2006; 19(1):49-51. 

Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M.  The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.  J Am Acad Dermatol 2006; 54(1):61-63. 

Berthelot C, Cather JC.  Violaceous-rimmed ulcers.  Proc (Bayl Univ Med Cent) 2005; 18(2):175-178. 

Race E, Berthelot C, Cather JC.  Painful nodule with induration and spreading erythema.  Proc (Bayl Univ Med Cent) 2005; 18(4):401-404. 

Cather JC, Cather JC.  A child with nonscarring alopecia.  Proc (Bayl Univ Med Cent) 2005; 18(3):269-272. 

Cather JC, Menter A.  Efalizumab: continuous therapy for chronic psoriasis.  Expert Opin Biol Ther 2005; 5(3):393-403. 

Cather JC, Menter A.  Combining traditional agents and biologics for the treatment of psoriasis.  Semin Cutan Med Surg 2005; 24(1):37-45. 

Gleaves TR, Cather JC, Menter A.  Oral erosions and cutaneous bullae.  Proc (Bayl Univ Med Cent) 2005; 18(1):71-73. 

Cather JC, Cather JC, Cockerell CJ.  Dysplastic nevi/ Melanoma paper (submitted). 

Menter A, Cather JC.  Psoriasis.  Derm Clin; 22(4) Guest Editors, preface. 

Cather JC, Cather JC, Cockerell CJ.  Update in the diagnosis of keratinocytic neoplasia.  Adv Dermatol 2004; 20:345-369. 

Cather JC, Cather JC, Menter A, Winterfield L. Changing Paradigms in Dermatology: Nuclear Hormone Receptors; 21:5, Sept/Oct 2003. 

Cather JC, Cather JC.  Diverse manifestations associated with a single dermatosis.  Proc (Bayl Univ Med Cent) 2003; 16(3):349-351. 

Cather JC, Cather JC, Menter MA.  Psoriasiform lesions on the trunk.  Proc (Bayl Univ Med Cent) 2003; 16(2):236-238. 

Cather JC, Cather JC, Menter A.  Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.  Expert Opin Biol Ther 2003; 3(2):361-370. 

Cather JC, Cather JC, Abramovits W.  Investigational therapies for psoriasis.  J Am Acad Dermatol 2003; 49(2 Suppl):S133-138. 

Goffe B, Cather JC.  Etanercept: an overview.  J Am Acad Dermatol 2003; 49(2 Suppl):S105-111. 

Cather JC, Cather JC, Menter A.  Update on botulinum toxin for facial aesthetics.  Dermatol Clin 2002; 20(4):749-761.

Cather JC, Vance EA, Menter MA.  Diverse cutaneous manifestations associated with a single disease.  Proc (Bayl Univ Med Cent) 2002; 15(4):433-436.

Cather JC, Cather JC, Menter MA.  Meandering linear pruritic lesion.  Proc (Bayl Univ Med Cent) 2002; 15(2):219-220.

Cather JC, Menter MA.  Leg lesions and velvety hyperpigmentation on the neck.  Proc (Bayl Univ Med Cent) 2002; 15(3):327-328.

Cather JC, Menter MA.  Vesicular eruption including the mouth.  Proc (Bayl Univ Med Cent) 2002; 15(1):93-94. 

Menter A, Cather JC.  Novel Therapies for Psoriasis.  Am J of Clin Dermatol 2002; 3(3):159-173. 

Cather JC, Menter MA.  Purplish, pruritic papules on the limbs.  Proc (Bayl Univ Med Cent) 2001; 14(4):449-451. 

Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Cather JC, Fernandez-Vina MA, Menter A.  In sights in psoriasis and other inflammatory diseases from large-scale gene expressions studies.  Hum Mol Genet 2001; 10:1793-1805. 

Cather JC, Menter MA.  Pruritic eruption on the chest, arms, and buttocks.  Proc (Bayl Univ Med Cent) 2001; 14(3):301-302. 

Cather JC, Menter MA.  Diffuse eruption of pigmented papules.  Proc (Bayl Univ Med Cent) 2001; 14(2):185-186. 

Cather JC, Abramovits W, Menter A.  Cyclosporine and tacrolimus in dermatology.  Dermatol Clin 2001; 19(1):119-137, ix. 

Cather JC, Menter MA.  Hair loss and plaquelike skin lesions.  Proc (Bayl Univ Med Cent) 2001; 14(1):101-103. 

Cather JC, Macknet MR, Menter MA.  Hyperpigmented macules and streaks.  Proc (Bayl Univ Med Cent) 2000; 13(4):405-406. 

Cather JC, Menter MA.  Red-brown skin lesions and pruritus.  Proc (Bayl Univ Med Cent) 2000; 13(3):297-299.

Duvic M, Feasel AM, Schwartz CA, Cather JC.  Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity.  Clin Lymphoma 2000; 1(2):141-145. 

Duvic M, Cather JC.  Emerging new therapies for cutaneous T-cell lymphoma.  Dermatol Clin 2000; 18(1):147-156. 

Duvic M, Cather JC.  Current status of Immunotoxin DAB389-IL2 (Ontak) in the management of Cutaneous T-cell lymphoma.  Current Practice In Medicine 1999; 2:167-70.

Cather JC, Cather JC, Soparkar CN, Nelson BR.  Ocular melanoma.  Cutis 1999; 63(5):285-292. 

Cather JC, Nelson BR, Duvic M.  Malignant melanoma--clinical diagnostic techniques.  Cutis 1999; 64(6):379-388. 

Cather JC, Lane D, Duvic M.  "Intrinsic" skin disorders in patients with HIV infection.  Dermatologic Therapy 1999; 12:1-11. 

Cather JC, Lane D, Heaphy MR, Nelson BR.  Finasteride--an update and review.  Cutis 1999; 64(3):167-172. 

Cather JC, Cohen PR.  Ichthyosiform sarcoidosis.  J Am Acad Dermatol 1999; 40(5 Pt 2):862-865. 

Cather JC, Farmer A, Jackow C, Manning JT, Shin DM, Duvic M.  Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma.  J Am Acad Dermatol 1998; 39(5 Pt 2):858-863.

Cather JC, Cohen PR. HIV infection. Dermis. DJ, Thiers BH, Bergdorf WHC, Raimer SS, eds. Clinical Dermatology.  Philadelphia, J.B. Lippincott Company.  1998;3:1-39. 

Duvic M, Cather JC, Maize J, Frankel A.  DAB389IL-2 diptheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma.  Am J Hematol 1998; 58:87-90. 

Cather JC, Jackow C, Yegge J, Hagemeister F, Duvic M.  Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome.  J Am Acad Dermatol 1998; 38(2 Pt 2):301-305. 

Cather JC, Cohen PR.  Herpes simplex virus type I infections.  J Gt Houst Dent Soc 1998; 69(6):12-13.

Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M.  Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.  Blood 1997; 89(1):32-40. 

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login